Monte Rosa Therapeutics (GLUE) Gains from Investment Securities (2021 - 2025)

Monte Rosa Therapeutics' Gains from Investment Securities history runs 5 years deep, the most recent figure standing at $3.8 million for Q3 2025.

• In Q3 2025, Gains from Investment Securities fell 66.88% year-over-year to $3.8 million; the TTM figure through Sep 2025 stood at $3.8 million (down 66.88% YoY), while the FY2025 annual figure was $14.1 million, up 21.36% from the prior year.
• Gains from Investment Securities was $3.8 million for Q3 2025 at Monte Rosa Therapeutics, up from $3.8 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $11.6 million in Q3 2024 to a low of -$131000.0 in Q1 2023.
• Historically, Gains from Investment Securities has averaged $2.7 million across 5 years, with a median of $639512.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities jumped 2825.0% in 2022, then slumped 204.8% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at -$4000.0 in 2021, then surged by 2825.0% to $109000.0 in 2022, then soared by 486.71% to $639512.0 in 2023, then jumped by 1712.54% to $11.6 million in 2024, then sank by 66.88% to $3.8 million in 2025.
• The last three Gains from Investment Securities figures came in at $3.8 million (Q3 2025), $3.8 million (Q2 2025), and $3.6 million (Q1 2025), per Business Quant data.